The invitation relates to methods for measurement of at least one advanced glycation endproduct (AGE) in a cerebrospinal fluid (CSF) sample that has been pre-treated with a protease, detergene or chaotropic agent and to the use of these methods in the assessment of neurodegenerative disease.
DETECTION OF ADVANCED GLYCATION ENDPRODUCTS IN A CEREBROSPINAL FLUID SAMPLE